UNLIMITED TURBO SHORT - GILEAD SCIENCES | Market Closed - Deutsche Boerse AG 20:50:29 05/07/2024 BST | ||
| 2.76 EUR | -1.43% |
|
| Current month | +4.55% | ||
| 1 month | -9.51% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 05/07/24 | 2.76 | -1.43% |
| 04/07/24 | 2.8 | +1.08% |
| 03/07/24 | 2.77 | +4.92% |
| 02/07/24 | 2.64 | +1.15% |
| 01/07/24 | 2.61 | -1.14% |
Delayed Quote Deutsche Boerse AG
Last update July 05, 2024 at 08:50 pm
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
BNP Paribas
|
| WKN | PE194F |
| ISIN | DE000PE194F8 |
| Date issued | 14/09/2022 |
| Strike | 96.22 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.25 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.03 € |
|---|---|
| Lowest since issue | 0.92 € |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
66.69
USD
Average target price
82.97
USD
Spread / Average Target
+24.41%
- Stock Market
- Certificates
- Certificat
